1 |
Hepp Rehfeldt SC, Majolo F, Goettert MI, Laufer S. c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases. Int J Mol Sci 2020;21(24).
|
2 |
Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. Front Pharmacol 2015;6:321.
|
3 |
Zulfiqar Z, Shah FA, Shafique S, Alattar A, Ali T, Alvi AM, et al. Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats. J Inflamm Res 2020;13:1185-205.
DOI
|
4 |
Meenakumari K, Bupesh G. Molecular docking of C-Jun-N-Terminal Kinase (Jnk) with amino-pyrimidine derivatives. Bioinformation 2020;16(6):462-7.
DOI
|
5 |
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31(2):455-61.
|
6 |
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.
DOI
|
7 |
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3(11):935-49.
DOI
|
8 |
Vieira TF, Sousa SF. Comparing AutoDock and Vina in Ligand/Decoy Discrimination for Virtual Screening. Appl Sci 2019;9(21).
|
9 |
Jordaan MA, Ebenezer O, Damoyi N, Shapi M. Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. Heliyon 2020;6(8):e04642.
|
10 |
Hohenberg P, Kohn W. Inhomogeneous Electron Gas. Phys Rev 1964;136(3B):B864-B871.
DOI
|